See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a medication used to treat several types of inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. While Cosentyx has demonstrated a favorable safety profile, like any medication, it may have potential risks and side effects. According to the drug's prescribing information, there are no specific heart-related risks directly associated with Cosentyx [2]. However, it is essential to consult with a healthcare professional for personalized medical advice.

It is also important to note that, according to DrugPatentWatch.com, Cosentyx's patent expiration is expected to occur in 2024 [3]. This information is relevant for patients and healthcare providers, as generic versions of the drug may become available after the patent expires, potentially impacting cost and accessibility.

In summary, while Cosentyx does not have specific heart-related risks, it is crucial to consult with a healthcare professional regarding any concerns or questions about the medication's safety and potential side effects.

Sources:
[1] Cosentyx (secukinumab) injection, for subcutaneous use [Prescribing Information]. Novartis Pharmaceuticals Corporation; 2021. Available from: <https://www.novartis.us/sites/www.novartis.us/files/cosentyx.pdf>
[2] Cosentyx.com. What is Cosentyx? <https://www.cosentyx.com/about-cosentyx>
[3] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/drugs/cosentyx-secukinumab>